Bristol Getting Eagerly Awaited First-Line Opdivo Lung Data Earlier Than Expected
Bristol-Myers Squibb Co. is moving up the timing on its eagerly awaited CheckMate-026 first-line lung cancer trial of Opdivo, with data now expected in the third quarter – earlier than prior guidance.
You may also be interested in...
Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.
Merck & Co. Inc. is heartened by market data showing about 70% of lung cancer patients who test positive for the PD-L1 biomarker are placed on Keytruda therapy, which could turn into an advantage as the PD-1 inhibitors move into the first-line setting.